To accelerate the translation of basic research on molecular and cellular repair of age-related damage into actual human therapies we directly support the creation of startups in this field.
The teams develop therapies in the area of Senolytics, Lysosomal Clearance, Induced Tissue Regeneration, Stemcell Restoration, Young Plasma Factors, AGE Breakers, Novel Cancer Therapies, and Aging Biomarkers.
Elevian is a Harvard spinout developing therapeutics to stimulate regenerative capacity, the body’s ability to repair itself, which declines as we age.
Elevian’s founders have identified circulating blood factors, including GDF11, which broadly stimulate regenerative capacity in aged animals across many organs and tissues (e.g. brain, heart, pancreas, muscle, and others). Initially planned indications include Alzheimer’s Disease, heart failure, Type II diabetes, and age-related muscle dysfunction.
Antoxerene uses proprietary next generation screening technology to identify small molecule compounds to target pathways of aging.
The team focusses on next generation screens with higher predictive value than traditional approaches and expects first on-target therapeutic candidates for the p53/MDM2 pathway, a major oncology target, and the p53/FOXO4 pathway, a newly identified pathway involved in cellular aging.
AgeX is applying technology relating to cell immortality and regenerative biology, to aging and age-related diseases.
The company has three initial areas of product development: pluripotent stem cell-derived brown adipocytes; vascular progenitors; and induced Tissue Regeneration. Initial planned indications for these products are Type II diabetes, cardiac ischemia, and cancer respectively.
When a cell reaches it's end of life or becomes damaged beyond repair, it is supposed to either kill itself or signal the immune system to remove it. Unfortunately, every so often this mechanism fails, the cell stays around indefinitely and starts poisoning its environment. Over time we accumulate more and more of these harmful, death-resistant senescent cells.
A recent study in rodents has shown that clearing senescent cells can both reduce the adverse effects of age-related diseases and extend the healthy lifespan by up to 35%.
Oisin is developing a cellular repair therapy based on a genetically-targeted intervention to clear senescent cells from our body.
Age-related macular degeneration (AMD) is the leading cause of vision loss among people over the age of 50.
AMD is thought to be caused by aggregation of A2E a toxic, non-degradable cellular waste product in our eye's retina cells.
Lysoclear is a molecular repair therapy based on the targeted delivery of exogenous A2E degrading enzymes to our retina cells to eliminate A2E, treat AMD and restore vision.
The team recently announced a Series-A offering to bring its product through Phase I clinical trials. LysoClear would be the first clinical candidate based on the repair and rejuvenation paradigm, pioneered by the SENS research foundation.
CellAge is aiming to increase human healthspan and reduce the incidence of age-related diseases by helping the human body destroy senescenct cells.
The team is focusing on a novel approach for this challenge by developing synthetic promoters for senescence cell detection and removal.
The joint expertise in senescence, synthetic biology and bioinformatics gives CellAge a unique angle on improving ways how gene therapies could be targeted to senescent cells.